Hormones, E.g., Prolactin, Thymosin, Growth Factors, Etc. Patents (Class 530/399)
-
Patent number: 8940305Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: July 2, 2014Date of Patent: January 27, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Publication number: 20150023960Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: March 8, 2013Publication date: January 22, 2015Inventors: Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
-
Patent number: 8937044Abstract: A method, for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.Type: GrantFiled: November 27, 2012Date of Patent: January 20, 2015Assignee: Thorn BioScience LLCInventor: James W. Lauderdale
-
Patent number: 8937043Abstract: The invention concerns a method for obtaining a highly enriched TGF-beta protein fraction in activated form, from a liquid solution rich in proteins said to be soluble in the aqueous phase of milk and/or of whey, said method comprising the following steps; a) adjusting soluble proteins purified at a concentration between 5 and 30 g/liter of solution; b) precipitating part of the whey proteins by acidic treatment of the solution thus obtained to a pH ranging between 4 and 5.5 and at a temperature ranging between 55° C. and 68° C.; c) carrying out a microfiltration of the treated solution by diafiltration, so as to obtain respectively a microfiltration retentate and a microfiltrate; d) recuperating the microfiltration retentate containing the protein fraction highly enriched in TGF-beta; e) drying the microfiltration retentate which has been subjected to diafiltration to obtain a powder highly enriched in TGF-beta.Type: GrantFiled: July 13, 2005Date of Patent: January 20, 2015Assignee: Piere Jouan Biotechnologies S.A.Inventors: Jean-Louis Maubois, Jacques Fauquant, Pierre Jouan, Michel Bourtourault
-
Publication number: 20150018665Abstract: According to some aspects, the invention relates to methods and compositions for evaluation of hemodynamic responses (e.g., using molecular imaging) with high sensitivity.Type: ApplicationFiled: July 15, 2014Publication date: January 15, 2015Applicant: Massachusetts Institute of TechnologyInventors: Alan Pradip Jasanoff, Adrian Lukas Slusarczyk, Mitul Desai, Mariya Barch, Gil G. Westmeyer
-
Publication number: 20150017699Abstract: The present invention is generally directed to internally functionalized graphene substrates, methods of making such substrates and methods of using such substrates. In one aspect, the present invention is a graphene substrate. The substrate comprises edge and non-edge regions. Organic or inorganic molecules are bound to the non-edge regions of the substrate, and the organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm2.Type: ApplicationFiled: July 9, 2014Publication date: January 15, 2015Applicant: NANOTECH BIOMACHINES, INC.Inventors: Jeffrey Alan McKinney, William Emerson Martinez
-
Patent number: 8933034Abstract: Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin.Type: GrantFiled: April 18, 2013Date of Patent: January 13, 2015Assignee: Brain-Gen BiotechInventor: Byron D. Ford
-
Patent number: 8932828Abstract: The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.Type: GrantFiled: September 29, 2010Date of Patent: January 13, 2015Assignee: Bolder Biotechnology, Inc.Inventors: Mary S. Rosendahl, George N. Cox, Daniel H. Doherty
-
Patent number: 8932591Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: May 15, 2012Date of Patent: January 13, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8933197Abstract: The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.Type: GrantFiled: August 15, 2008Date of Patent: January 13, 2015Assignee: Amunix Operating Inc.Inventors: Willem P. Stemmer, Volker Schellenberger
-
Patent number: 8927492Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.Type: GrantFiled: April 23, 2014Date of Patent: January 6, 2015Assignee: Eli Lilly and CompanyInventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
-
Patent number: 8927485Abstract: The present invention generally provides methods for the site-specific modification of peptides, polypeptides, and proteins, e.g., granulocyte macrophage colony-stimulating factor, human superoxide dismutase, annexin, leptin, antibodies and the like, cytokines and chemokines, at their N-termini and at sites at which unnatural aminoacids have been introduced along the protein framework. The modifications described herein can be used for the synthesis and application of the adducts in radio-labeling, molecular imaging and protein therapeutic applications, and the treatment of disorders such as rheumatoid arthritis, lupus erythematosus, psoriasis, multiple sclerosis, type-1 diabetes, Crohn's disease, and systemic sclerosis, Alzheimer disease, cancer, liver disease (e.g., alcoholic liver disease), and cachexia.Type: GrantFiled: February 18, 2011Date of Patent: January 6, 2015Assignee: Advanced Proteome Therapeutics Inc.Inventors: Alexander Krantz, Peng Yu
-
Patent number: 8927493Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.Type: GrantFiled: October 8, 2009Date of Patent: January 6, 2015Assignee: Kringle Pharma, Inc.Inventors: Katsuro Tomita, Hiroyuki Tsuchiya, Katsuhiko Kitaoka, Junsuke Nakase, Keigo Hanada, Kunio Matsumoto
-
Patent number: 8927496Abstract: A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogs, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.Type: GrantFiled: October 30, 2012Date of Patent: January 6, 2015Assignee: Thorn BioScience LLCInventor: James W. Lauderdale
-
Publication number: 20150005235Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.Type: ApplicationFiled: September 3, 2014Publication date: January 1, 2015Inventors: Jennifer R. Cochran, Adam Silverman, Douglas Jones, Niv Papo
-
Publication number: 20150005233Abstract: This invention provides compounds, compositions, and methods for treating hypogly.Type: ApplicationFiled: February 8, 2013Publication date: January 1, 2015Applicant: Seneb Biosciences, Inc.Inventor: Shawn DeFrees
-
Publication number: 20150004667Abstract: The present invention is generally directed to functionalized graphene substrates, methods of making such substrates and methods of using such substrates. In one aspect, the present invention provides a graphene substrate. The substrate comprises edge and non-edge regions, and organic or inorganic molecules are bound to the edge regions of the substrate. The organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm.Type: ApplicationFiled: May 23, 2014Publication date: January 1, 2015Applicant: NANOTECH BIOMACHINES, INC.Inventors: Jeffrey Alan McKinney, William Emerson Matinez
-
Publication number: 20140377178Abstract: The present invention relates to a method of labelling biological molecules with 18F, via attachment to fluorine to a macrocyclic metal complex of a non-radioactive metal, where the metal complex is conjugated to the biological molecule. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.Type: ApplicationFiled: January 22, 2013Publication date: December 25, 2014Applicants: UNIVERSITY OF SOUTHAMPTON, GE HEALTHCARE LIMITEDInventors: Rajiv Bhalla, Sajinder Kaur Luthra, Gill Reid, I, William Levason
-
Patent number: 8916522Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein the FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.Type: GrantFiled: July 30, 2013Date of Patent: December 23, 2014Assignee: ProChon Biotech Ltd.Inventors: Oren Bogin, Avner Yayon
-
Patent number: 8916157Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: August 6, 2014Date of Patent: December 23, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8916158Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: August 6, 2014Date of Patent: December 23, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Publication number: 20140371136Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.Type: ApplicationFiled: January 10, 2014Publication date: December 18, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland
-
Publication number: 20140369978Abstract: The present invention is directed to GDF-5 related proteins having an improved capability of inducing cartilage formation and a reduced capability of inducing bone formation. The novel proteins are particularly useful in the treatment of cartilage defects, wherein the formation of bone tissue is undesirable.Type: ApplicationFiled: December 5, 2012Publication date: December 18, 2014Applicant: BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA MBHInventors: Frank Ploger, Florian Wagner
-
Patent number: 8911741Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: July 2, 2014Date of Patent: December 16, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8907064Abstract: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.Type: GrantFiled: October 18, 2007Date of Patent: December 9, 2014Assignee: Ambrx, Inc.Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. DiMarchi, Anna-Maria Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
-
Publication number: 20140356384Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: ApplicationFiled: August 15, 2014Publication date: December 4, 2014Inventors: Jeffrey A. Hubbell, Stéphane Kontos, Karen Y. Dane
-
Publication number: 20140356286Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.Type: ApplicationFiled: April 21, 2014Publication date: December 4, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Adam Silverman, Douglas Jones, Niv Papo
-
Publication number: 20140356378Abstract: Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicant: GENERA ISTRAZIVANJA d.o.oInventors: Slobodan VUKICEVIC, Lovorka GRGUREVIC, Boris MACEK
-
Publication number: 20140356326Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.Type: ApplicationFiled: December 10, 2013Publication date: December 4, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
-
Patent number: 8900593Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).Type: GrantFiled: January 9, 2013Date of Patent: December 2, 2014Assignee: Indiana University Research and Technology CorporationInventors: Jonathan Day, James Patterson, Joseph Chabenne, Maria DiMarchi, David L. Smiley, Richard D. DiMarchi
-
Patent number: 8901081Abstract: The present invention is related to a anticancer composition comprising full length GRS protein or a fragment thereof, a nucleic acid encoding the GRS protein or a fragment thereof. Since the GRS proteins or fragments thereof have activity to induce apoptosis of cancer cell specifically, a composition comprising the GRS proteins or fragments thereof or a nucleic acid encoding thereof may be useful to treatment of cancer.Type: GrantFiled: October 12, 2009Date of Patent: December 2, 2014Assignee: SNU R&DB FoundationInventors: Sunghoon Kim, Min Chul Park
-
Publication number: 20140349931Abstract: The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, there is the risk of progression to invasive cancer and/or the risk or recurrent disease. The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells is administered for cancer cell killing.Type: ApplicationFiled: December 20, 2012Publication date: November 27, 2014Applicants: THE EUROPEAN MOLECULAR BIOLOGY LABORATORY, FAHY GURTEEN LABORATORIES LTD., UCL BUSINESS PLCInventors: Jan Ellenberg, Beate Neumann, Marco Loddo, Gareth Williams, Kai Stoeber
-
Patent number: 8889131Abstract: The present invention is directed to methods of treating or preventing a metabolic disease or disorder and cardiovascular complications and other complications thereof by administering agents that inhibit the NOTCH signaling pathway. In addition, the invention encompasses methods for determining whether a patient is at increased risk for developing these conditions by determining the amount, function, or activity of NOTCH pathway components in biological samples derived from the patient or in imaging analysis.Type: GrantFiled: May 1, 2012Date of Patent: November 18, 2014Assignee: The Brigham and Women's Hospital, Inc.Inventors: Masanori Aikawa, Daiju Fukuda, Tetsuro Miyazaki, Elena Aikawa
-
Patent number: 8889426Abstract: The present invention is directed to a method of treating hypophosphatemia in a subject. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed.Type: GrantFiled: May 18, 2012Date of Patent: November 18, 2014Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz, Anna V. Eliseenkova
-
Publication number: 20140336254Abstract: A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ?-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.Type: ApplicationFiled: April 14, 2014Publication date: November 13, 2014Inventors: Jeffery W. Kelly, Sungwook Choi
-
Publication number: 20140336367Abstract: The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide.Type: ApplicationFiled: February 15, 2013Publication date: November 13, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Kang Ting, Chia Soo
-
Patent number: 8883726Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.Type: GrantFiled: August 13, 2013Date of Patent: November 11, 2014Assignee: Eli Lilly and CompanyInventors: Craig Duane Dickinson, David Albert Driver, Ryan James Darling, Malgorzata Donata Gonciarz, Radmila Micanovic
-
Publication number: 20140329748Abstract: Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.Type: ApplicationFiled: August 8, 2012Publication date: November 6, 2014Applicant: FERRING BVInventor: Joan-Carles Arce
-
Publication number: 20140329745Abstract: The present invention provides a human insulin analogue, an acylated derivative thereof and a physiologically acceptable salt. The present invention further provides a preparation method for the insulin analogue and an application of the insulin analogue as a therapeutic agent, and particularly as a diabetes mellitus therapeutic agent.Type: ApplicationFiled: November 22, 2012Publication date: November 6, 2014Inventors: Piaoyang Sun, Lianshan Zhang, Jiajian Liu, Jijun Yuan, Chunqian Fang, Changan Sun, Hengli Yuan, Yali Wang
-
Publication number: 20140329750Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventors: Henrik Sune Andersen, Nils Langeland Johansen, Jens Buchardt, Leif Noerskov-Lauritsen
-
Publication number: 20140322368Abstract: Scars, stretch marks, keloids, keratosis, and other skin lesions can be ameliorated through topical application of a composition containing a fortified botanical complex inhibiting tryptase and chymase. A flavonoid with antioxidant properties valuable in inflammatory stress; blocking the release of histamine, inhibiting leukocytic elastase and strengthening the protective properties surrounding the extracellular matrix. Primary wound healing occurs through the release of platelet derived growth factors stimulating the production of procollagen and increasing the density of water holding skin matrix cells which provide unencumbered moisture to the skin. The formula peptides are matrikines They act in synergy to restore and maintain the skin's appearance by activating the neosynthesis of extracellular matrix molecules.Type: ApplicationFiled: April 24, 2014Publication date: October 30, 2014Inventor: ALVIN DAVID NEEDLEMAN
-
Publication number: 20140323402Abstract: The present invention relates to water-soluble protein carrier-linked prodrugs wherein the protein carrier comprises an amino acid sequence consisting of at least 100 amino acid residues forming random coil conformation and comprising alanine, serine and proline residues. It further relates to pharmaceutical compositions comprising said water-soluble protein carrier-linked prodrugs, their use as a medicament as well as methods of treatment and administration.Type: ApplicationFiled: August 10, 2012Publication date: October 30, 2014Applicant: Ascendis Phama A/SInventors: Ulrich Hersel, Dirk Vetter
-
Publication number: 20140322752Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.Type: ApplicationFiled: March 26, 2014Publication date: October 30, 2014Applicant: Biogen Idec MA Inc.Inventors: Anthony Rossomando, R. Blake Pepinsky, BangJian Gong
-
Publication number: 20140322720Abstract: There is provided a composition for diagnosing, treating, and preventing an age-related macular degeneration and a method for diagnosing an age-related macular degeneration.Type: ApplicationFiled: December 4, 2013Publication date: October 30, 2014Applicant: KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP.Inventors: Hyewon CHUNG, Hyung-Soon PARK, Gum-Yong KANG
-
Publication number: 20140323396Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: ApplicationFiled: January 29, 2014Publication date: October 30, 2014Applicant: AMGEN INC.Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
-
Patent number: 8871721Abstract: A pharmaceutical composition for treating or preventing peritoneal dissemination is provided. The pharmaceutical composition includes an effective dose of connective tissue growth factor (CTGF) and a pharmaceutically acceptable carrier thereof.Type: GrantFiled: March 1, 2012Date of Patent: October 28, 2014Inventors: Min-Liang Kuo, Been-Ren Lin, Cheng-Chi Chang, Chiung-Nine Chen
-
Patent number: 8871915Abstract: The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided.Type: GrantFiled: January 11, 2013Date of Patent: October 28, 2014Assignee: New York University School of MedicineInventor: Chuanju Liu
-
Publication number: 20140315253Abstract: Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair.Type: ApplicationFiled: June 30, 2014Publication date: October 23, 2014Inventors: Jianwu Dai, Bing Chen, Hang Lin, Wenjie Sun, Wenxue Zhao
-
Publication number: 20140316109Abstract: Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair.Type: ApplicationFiled: June 30, 2014Publication date: October 23, 2014Inventors: Jianwu Dai, Bing Chen, Hang Lin, Wenjie Sun, Wenxue Zhao
-
Patent number: 8865647Abstract: If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous injection.Type: GrantFiled: November 1, 2010Date of Patent: October 21, 2014Assignee: Novo Nordisk A/SInventors: Helle Naver, Svend Havelund, Peter Madsen